版本:
中国

BRIEF-Allergan says FDA accepts supplemental new drug application for avycaz

Oct 11 Allergan Plc:

* FDA accepts supplemental new drug application (SNDA) for avycaz (ceftazidime and avibactam)

* Allergan plc - FDA is expected to take action on filing in q1 of 2017.

* Allergan - application seeks to expand avycaz label to include phase 3 clinical data for treatment of complicated urinary tract infections

* Allergan plc - application included results from a phase 3 study evaluating efficacy and safety of avycaz for treatment of patients with cuti Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐